Lineage Sues Solar-Panel Company, Contractor Over L.A. Warehouse Fire
Plus, Houthi militants expand control near a strategic Red Sea chokepoint, and the Amazon plane crash is putting a spotlight on freight carrier 21 Air.
Lineage Sues Solar-Panel Operator Over L.A. Warehouse Fire
The world's largest cold-storage operator claims negligence caused a massive blaze and is seeking over $1 billion in damages.
Lineage: The Recovery May Be Delayed, But Not Broken
Lineage (LINE) remains a Buy, with valuation offering a strong margin of safety despite near-term macro headwinds and operational volatility. Q2 results beat expectations; AFFO per share fell 6.2% to $0.76, but guidance was raised to $2.80–$3.05 for full year. LINE's technological and operational advantages drive competitiveness, yet higher leverage (net debt/EBITDA at 6.0x) and industry risks require close monitoring.
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
Lineage, Inc. (LINE) Q2 2026 Earnings Call Transcript
Lineage, Inc. (LINE) Q2 2026 Earnings Call Transcript
Lineage Q2 Earnings Call Highlights
Lineage NASDAQ: LINE reported second-quarter results that exceeded its internal expectations and consensus estimates as warehouse occupancy improved and cost-control efforts helped offset continued trade-related volume pressure.
Compared to Estimates, Lineage, Inc. (LINE) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Lineage, Inc. (LINE) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Lineage, Inc. (LINE) Beats Q2 FFO and Revenue Estimates
Lineage, Inc. (LINE) came out with quarterly funds from operations (FFO) of $0.76 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to FFO of $0.81 per share a year ago.
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan
Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.
Lineage: Don't Mistake A Cyclical Slump For A Broken Business
Lineage remains a Buy, offering a margin of safety and re-rating potential despite near-term macro and operational headwinds. Q1 saw AFFO per share decline 9.3% to $0.78, but guidance for Adj. EBITDA ($1.25–$1.3B) and AFFO per share ($2.75–$3.00) were maintained. LINE's cost reduction plan and automation investments target $110M annualized EBITDA improvement in 3–5 years, supporting long-term upside.
Lineage: Another Serious Fire Could Spell Trouble
Lineage Logistics faces significant operational and financial risks after two catastrophic fires at major cold storage facilities. Recent fires have led to lawsuits, public health concerns, and potential long-term brand damage, particularly in Los Angeles. Immediate costs include emergency relief and remediation, while longer-term impacts may include higher insurance premiums and increased operating expenses.
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing manufacturing initiatives built around its AlloSCOPE platform.
